S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:JANX

Janux Therapeutics Stock Forecast, Price & News

$21.24
+0.11 (+0.52 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.55
$22.12
50-Day Range
$18.94
$34.35
52-Week Range
$16.32
$37.99
Volume79,784 shs
Average Volume220,086 shs
Market Capitalization$883.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive JANX News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Janux Therapeutics

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Headlines

Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $21.13
October 18, 2021 |  americanbankingnews.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update
October 17, 2021 |  americanbankingnews.com
Janux Therapeutics (NASDAQ:JANX) Trading 6.4% Higher
October 14, 2021 |  americanbankingnews.com
Janux Therapeutics (NASDAQ:JANX) Stock Price Down 11.1%
October 12, 2021 |  americanbankingnews.com
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $21.31
October 11, 2021 |  americanbankingnews.com
Janux Therapeutics (NASDAQ:JANX) Stock Price Down 4.4%
October 5, 2021 |  americanbankingnews.com
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $21.63
October 1, 2021 |  americanbankingnews.com
Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $22.93
September 30, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JANX
Employees
16
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$883.84 million
Next Earnings Date
11/9/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.75 out of 5 stars

Medical Sector

858th out of 1,361 stocks

Pharmaceutical Preparations Industry

420th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Janux Therapeutics (NASDAQ:JANX) Frequently Asked Questions

Is Janux Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Janux Therapeutics stock.
View analyst ratings for Janux Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Janux Therapeutics?

Wall Street analysts have given Janux Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Janux Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Janux Therapeutics?

Janux Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 1,810,000 shares, an increase of 37.1% from the September 15th total of 1,320,000 shares. Based on an average daily trading volume, of 217,300 shares, the short-interest ratio is currently 8.3 days. Approximately 8.6% of the shares of the stock are short sold.
View Janux Therapeutics' Short Interest
.

When is Janux Therapeutics' next earnings date?

Janux Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Janux Therapeutics
.

How were Janux Therapeutics' earnings last quarter?

Janux Therapeutics, Inc. (NASDAQ:JANX) issued its quarterly earnings data on Tuesday, August, 10th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.48. The business had revenue of $0.48 million for the quarter.
View Janux Therapeutics' earnings history
.

What price target have analysts set for JANX?

4 analysts have issued 12-month price targets for Janux Therapeutics' shares. Their forecasts range from $35.00 to $35.00. On average, they expect Janux Therapeutics' stock price to reach $35.00 in the next year. This suggests a possible upside of 64.8% from the stock's current price.
View analysts' price targets for Janux Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Janux Therapeutics' key executives?

Janux Therapeutics' management team includes the following people:
  • Dr. David Alan Campbell, Pres, CEO & Director (Age 61, Pay $585.81k)
  • Mr. Tighe M. Reardon C.F.A., CPA, CPA, Acting Chief Financial Officer (Age 45)
  • Mr. Tommy Diraimondo Ph.D., Director of Research
  • Mr. Andy Hollman Meyer, Chief Bus. Officer (Age 37)
  • Mr. Charles M. Winter, Sr. VP of Chemistry, Manufacturing & Controls
  • Dr. Wayne Godfrey M.D., Chief Medical Officer

When did Janux Therapeutics IPO?

(JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

What is Janux Therapeutics' stock symbol?

Janux Therapeutics trades on the NASDAQ under the ticker symbol "JANX."

When does Janux Therapeutics' lock-up period expire?

Janux Therapeutics' lock-up period expires on Wednesday, December 8th. Janux Therapeutics had issued 11,400,000 shares in its public offering on June 11th. The total size of the offering was $193,800,000 based on an initial share price of $17.00. After the expiration of Janux Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Janux Therapeutics?

Shares of JANX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Janux Therapeutics' stock price today?

One share of JANX stock can currently be purchased for approximately $21.24.

How much money does Janux Therapeutics make?

Janux Therapeutics has a market capitalization of $883.84 million.

How many employees does Janux Therapeutics have?

Janux Therapeutics employs 16 workers across the globe.

What is Janux Therapeutics' official website?

The official website for Janux Therapeutics is www.januxrx.com.

How can I contact Janux Therapeutics?

The company can be reached via phone at 858-750-4700 or via email at [email protected].


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.